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Abstract
Introduction: MicroRNAs (miRNAs), endogenous small noncoding RNAs regulating the activities of target mRNAs and 
cellular processes, are present in human plasma in a stable form. In this study, we investigated whether miRNAs are also 
stably present in synovial fluids and whether plasma and synovial fluid miRNAs could be biomarkers of rheumatoid 
arthritis (RA) and osteoarthritis (OA).
Methods: We measured concentrations of miR-16, miR-132, miR-146a, miR-155 and miR-223 in synovial fluid from 
patients with RA and OA, and those in plasma from RA, OA and healthy controls (HCs) by quantitative reverse 
transcription-polymerase chain reaction. Furthermore, miRNAs in the conditioned medium of synovial tissues, 
monolayer fibroblast-like synoviocytes, and mononuclear cells were examined. Correlations between miRNAs and 
biomarkers or disease activities of RA were statistically examined.
Results: Synovial fluid miRNAs were present and as stable as plasma miRNAs for storage at -20°C and freeze-thawing 
from -20°C to 4°C. In RA and OA, synovial fluid concentrations of miR-16, miR-132, miR-146a, and miR-223 were 
significantly lower than their plasma concentrations, and there were no correlation between plasma and synovial fluid 
miRNAs. Interestingly, synovial tissues, fibroblast-like synoviocytes, and mononuclear cells secreted miRNAs in distinct 
patterns. The expression patterns of miRNAs in synovial fluid of OA were similar to miRNAs secreted by synovial tissues. 
Synovial fluid miRNAs of RA were likely to originate from synovial tissues and infiltrating cells. Plasma miR-132 of HC 
was significantly higher than that of RA or OA with high diagnosability. Synovial fluid concentrations of miR-16, miR-
146a miR-155 and miR-223 of RA were significantly higher than those of OA. Plasma miRNAs or ratio of synovial fluid 
miRNAs to plasma miRNAs, including miR-16 and miR-146a, significantly correlated with tender joint counts and 28-
joint Disease Activity Score.
Conclusions: Plasma miRNAs had distinct patterns from synovial fluid miRNAs, which appeared to originate from 
synovial tissue. Plasma miR-132 well differentiated HCs from patients with RA or OA, while synovial fluid miRNAs 
differentiated RA and OA. Furthermore, plasma miRNAs correlated with the disease activities of RA. Thus, synovial fluid 
and plasma miRNAs have potential as diagnostic biomarkers for RA and OA and as a tool for the analysis of their 
pathogenesis.
Introduction
MicroRNAs (miRNAs) are endogenous small (approxi-
mately 22 nucleotides) noncoding RNAs and regulate the
activities of target mRNAs by binding at sites in the 3'
untranslated region of the mRNAs [1,2], and currently
more than 721 human miRNAs have been registered [3].
miRNAs have been implicated in important cellular pro-
cesses such as lipid metabolism [4], apoptosis [5], differ-
entiation [6], organ development [7] and malignant
tumors [8-12], and there is a prediction that one-third of
all mRNAs may be regulated by miRNAs [13]. Recently
Mitchell et al showed that miRNAs are present in human
plasma in a remarkably stable form that is protected from
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endogenous RNase activity [14]. Furthermore, miRNAs
are present in dried biological fluids such as semen,
saliva, vaginal secretions, and menstrual blood [15], and
expected to be diagnostic and prognostic biomarkers of
various cancers [14,16,17].
Several cellular or tissue miRNAs associate with rheu-
matoid arthritis (RA). The expressions of miR-155, miR-
146a, and miR-124a in RA fibroblast-like synoviocytes
(FLSs); miR-146 and miR-155 in RA synovial tissue; or
miR-146a, miR-155, miR-132, and miR-16 in RA periph-
eral blood (PB) mononuclear cells (MNCs) are upregu-
lated compared with osteoarthritis (OA) or healthy
controls (HCs) [18-21].
On the other hand, there is no report associated with
m i R N A s  i n  p l a s m a  o r  s y n o v i a l  f l u i d  o f  R A  o r  O A
patients. In this study, we investigated the presence and
the stability of miRNAs in synovial fluid, and compared
synovial fluid miRNAs with plasma miRNAs. We also
examined the differences in the expression of plasma
miRNAs or in synovial fluid miRNAs between RA, OA
and HC, and the correlation of plasma or synovial fluid
miRNAs with disease activities of RA.
Materials and methods
Preparation of blood and joint fluid samples
Ethical approval for this study was granted by the ethics
committee of Kyoto University Graduate School and Fac-
ulty of Medicine. Informed consent was obtained from
108 participants (40 with RA, 38 with knee OA, and 30 as
HC, Tables 1 and 2). According to the request of the eth-
ics committee, HCs were limited between 20 and 65 years
old. RA and OA were diagnosed according to the criteria
of the American College of Rheumatology [22,23]. Both
peripheral blood and synovial fluid were obtained from
20 patients with RA and 22 patients with OA. Blood sam-
ples were collected with ethylenediaminetetraacetic acid
dipotassium salt (EDTA-2K) containing tube to separate
plasma. Both of samples were centrifuged 400 g for seven
minutes and stored at -20°C until analyses.
Preparation for conditioned medium of cells and tissues
PB or joint specimens from RA and OA patients were
obtained during joint surgery or from an outpatient
clinic. FLSs of RA and OA patients were prepared as pre-
viously described [24]. After three to eight passages, FLSs
were plated on six-well plates (Corning, NY, USA) in Dul-
becco's Modified Eagle's Medium (DMEM; Sigma
Aldrich, St. Louis, MO, USA) containing 10% fetal bovine
serum (FBS; ICN, Aurora, OH, USA). At confluence,
FLSs were washed three times with phosphate-buffered
saline (PBS) and cultured in 2 ml of serum-free DMEM
for 48 h. Serum-free medium was used to exclude the
contamination of miRNAs in bovine serum.
Synovial tissues of 30 mg were incubated at 37°C in 1
ml of serum-free DMEM for 48 h. MNCs from PB and
synovial fluid were collected using Histopaque-1077
(Sigma Aldrich) as previously described [24]. One million
MNCs were placed on 12-well plates (Corning) and cul-
tured in 1 ml of serum-free RPMI 1640 (Sigma Aldrich)
for 48 h. The resultant culture medium was collected,
centrifuged 800 g for 10 minutes and stored as condi-
tioned medium at -20°C until analyses.
RNA isolation
A hundred μl of human plasma or synovial fluid was
thawed on ice, diluted with 150 μl of RNase free water
and lysed with 750 μl of a phenol-based reagent for liquid
sample, Isogen LS (Nippongene, Toyama, Japan). To nor-
malize possible sample-to-sample variation caused by
RNA isolation, 25 fmol (total volume of 5 μl) of synthetic
C. elegans miRNA cel-miR-39 (Hokkaido System Science,
Sapporo, Japan), which has no homologous sequences in
humans, were added to each denatured sample. Samples
were homogenized, incubated for five minutes, added
with 0.2 ml chloroform, shaked vigorously for 15 seconds,
incubated for three minutes and centrifuged at 12,000 g
for 15 minutes at 4°C. Then 300 μl of aqueous phase was
applied to High Pure miRNA Isolation Kit (Roche
Applied Science, Mannheim, Germany) according to
manufacture's protocol.
Total RNA included in 300 μl of conditioned medium
was also isolated with High Pure miRNA Isolation Kit
according to manufacture's protocol for liquid sample.
After samples were mixed with binding buffer, which
inhibits RNase activities, 25 fmol of synthetic cel-miR-39
was spiked.
Reverse transcription and quantitation of miRNAs by real-
time PCR
Reverse transcription was performed using NCode VILO
miRNA cDNA Synthesis Kit (Invitrogen, Carlsbad, CA,
USA) according to the manufacture's protocol. Using
EXPRESS SYBR GreenER qPCR SuperMix (Invitrogen),
real-time polymerase chain reaction (PCR) was carried
out on an Applied BioSystems 7300 Real-Time PCR Sys-
tem (Applied BioSystems, Tokyo, Japan) with standard
plasmids generated as in the next paragraph. Forward
primers were designed according to NCode miRNA
Database [25]. Data were analyzed with SDS Relative
Quantification Software version 1.3 (Applied BioSystems,
Tokyo, Japan).
Primer sequences were as follows: for hsa-miR-16, 5'-
TAG-CAG-CAC-GTA-AAT-ATT-GGC-G-3'; for hsa-
miR-132, 5'-TAA-CAG-TCT-ACA-GCC-ATG-GTC-G-
3'; for hsa-miR-146a, 5'-TGA-GAA-CTG-AAT-TCC-
ATG-GGT-T-3'; for hsa-miR-155, 5'-TTA-ATG-CTA-
ATC-GTG-ATA-GGG-GTA-3'; for hsa-miR-223, 5'-Murata et al. Arthritis Research & Therapy 2010, 12:R86
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TGT-CAG-TTT-GTC-AAA-TAC-CCC-A-3'; for cel-
miR-39, 5'-CGT-CAC-CGG-GTG-TAA-ATC-AGC-
TTG-3'.
TA Cloning of PCR products and generation of standard 
curve
T o  v e r i f y  t h e  P C R  p r o d u c t s  a n d  t o  g e n e r a t e  s t a n d a r d
curves of miRNAs, thymine adenine (TA) cloning was
performed. The resultant reaction buffers of preliminary
real-time PCR were directly put in TA cloning using
pTAC-1 vector (BioDynamics Laboratory, Tokyo, Japan)
according to the manufacture's protocol. We verified that
the sequences of inserted approximately 60 nucleotides
(about 20 nucleotides of miRNA and about 40 nucle-
otides added at the reverse transcripts) were all correct,
and could not find pre-miRNAs inserted into the vector.
Plasmids with known copy number were put into real-
time PCR over an empirically-derived range of copies to
generate standard curves for each of the miRNA. Abso-
lute copy number of each target miRNA and spiked cel-
miR-39 in samples was obtained according to the gener-
ated standard curves. The concentrations of target miR-
NAs in each sample were calculated according to the
obtained absolute copy numbers of spiked cel-miR-39
with known concentration and target miRNAs.
Statistical analysis
Data were presented as the mean ± standard deviation.
Statistical analyses were performed using StatView Ver.5
for Windows (Hulinks, Tokyo, Japan). Differences
between two groups were analyzed with Student's t-test.
Differences among three groups were analyzed with Bon-
Table 1: Clinical features of the participants who contributed plasma
Characteristics RA OA HC
Number of participants 30 30 30
Sex, male/female 8/22 7/23 13/17
Age, mean (range) 60.1 (22 to 77) 75.1 (65 to 89) 46.5 (32 to 62)
Disease duration (y), mean (range) 10.4 (0.3 to 32) NA NA
Positive anti-CCP antibody, n (%) 10 (90.9%)† NA NA
ESR (mm), mean (range) 37.2 (4 to 116) NA NA
CRP (mg/dl), mean (range) 2.1 (0 to 9.6) NA NA
MMP3 (ng/ml), mean (range) 290.1 (32.4 to 800) NA NA
DAS28, mean (range) 4.4 (1.7 to 7.1) NA NA
SJC, mean (range) 4.3 (0 to 13) NA NA
TJC, mean (range) 4.5 (0 to 27) NA NA
VAS 42.3 (0 to 95) NA NA
Steinbrocker Stage, n I: 4, II: 3, III: 6, IV: 17 NA NA
Steinbrocker Class, n I: 1, II: 24, III: 5, IV: 0 NA NA
Kellgren/Lawrence grade, n NA I: 0, II: 0, III: 9, IV: 21 NA
Medication, n (%)
Prednisolone 21 (70%) NA NA
Methotrexate 18 (60%) NA NA
Infliximab 8 (27%) NA NA
Eternercept 2 (6.7%) NA NA
Tocilizumab 2 (6.7%) NA NA
Tacrolimus 2 (6.7%) NA NA
Salazosulfapyridine 6 (20%) NA NA
Bucillamine 5 (17%) NA NA
Mizoribine 0 (0%) NA NA
Gold 1 (3.3%) NA NA
CCP, cyclic citrullinated peptide; CRP, C-reactive protein; DAS28, 28-joint Disease Activity Score; ESR, erythrocyte sedimentaition ratio; HC, 
healthy control; MMP-3, metalloproteinase-3; NA, not applicable; OA, osteoarthritis; RA, rheumatoid arthritis; SJC, swollen joint count; TJC, 
tender joint count; VAS, visual analogue scale of general health;
† anti-CCP antibodies of 10 patients were positive among 11 patients examined.Murata et al. Arthritis Research & Therapy 2010, 12:R86
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ferroni method. Correlations with miRNA concentra-
tions and other clinical factors were analyzed with
Pearson product-moment correlation coefficient. The
ROCKIT software version 0.9B (Metz, Herman, & Roe,
The University of Chicago, Chicago, IL, USA) was used to
calculate Receiver Operating Characteristic (ROC) curve
values. A P-value less than 0.05 was considered statisti-
cally significant.
Results
The presence and the stability of miRNAs in plasma and 
synovial fluid
It has not been reported whether miRNAs are present in
the synovial fluid in a stable form as previously reported
in plasma. Both of miR-16 and miR-223 were detectable
in both of plasma and synovial fluid (Figure 1). Then, we
investigated the stability of plasma and synovial fluid
miRNAs for the storage at -20°C and freeze-thaw cycles
from -20°C to 4°C. Storage of plasma and synovial fluid at
-20°C for up to seven days had minimal effect on concen-
trations of miR-16 or miR-223 (Figure 1). But concentra-
tions of miRNAs slightly decreased with the number of
freeze-thaw cycles (up to eight times), with statistical sig-
nificances (Figure 1).
Plasma and synovial fluid miRNAs had distinct profiles
It is unclear how miRNAs are produced in plasma and
synovial fluid. Especially, it is an interesting question
whether plasma miRNAs just penetrate into synovial
fluid, or tissues facing joint space are generating miRNAs.
Table 2: Clinical features of the participants who contributed synovial fluid
Characteristics RA OA
Number of participants 30 30
Sex, male/female 6/24 6/24
Age, mean (range) 63.1 (32 to 88) 75.3 (67 to 89)
Disease duration (y), mean (range) 13.0 (0.5 to 50) NA
Positive anti-CCP antibody, n (%) 10 (83.3%)¶ NA
ESR (mm), mean (range) 49.6 (4 to 116) NA
CRP (mg/dl), mean (range) 3.1 (0 to 13.9) NA
MMP3 (ng/ml), mean (range) 362.7 (43.2 to 800) NA
DAS28, mean (range) 4.9 (2.2 to 7.1) NA
SJC, mean (range) 4.9 (0 to 17) NA
TJC, mean (range) 5.1 (0 to 27) NA
VAS 52.1 (10 to 95) NA
Steinbrocker Stage, n I: 3, II: 3, III: 5, IV: 19 NA
Steinbrocker Class, n I: 1, II: 22, III: 7, IV: 0 NA
Kellgren/Lawrence grade, n NA I: 0, II: 0, III: 11, IV: 19
Medication, n (%)
Prednisolone 20 (67%) NA
Methotrexate 15 (50%) NA
Infliximab 3 (10%) NA
Eternercept 1 (3.3%) NA
Tocilizumab 0 (0%) NA
Tacrolimus 2 (6.7%) NA
Salazosulfapyridine 8 (27%) NA
Bucillamine 6 (20%) NA
Mizoribine 1 (3.3%) NA
Gold 2 (6.7%) NA
CCP, cyclic citrullinated peptide; CRP, C-reactive protein; DAS28, 28-joint Disease Activity Score; ESR, erythrocyte sedimentaition ratio; MMP-
3, metalloproteinase-3; NA, not applicable; OA, osteoarthritis; RA, rheumatoid arthritis; SJC, swollen joint count score; TJC, tender joint count; 
VAS, visual analogue scale of general health.
¶anti-CCP antibodies of 10 patients were positive among 12 patients examined.Murata et al. Arthritis Research & Therapy 2010, 12:R86
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In RA, the average plasma concentrations of miR-16,
miR-132, miR-146a, miR-155 and miR-223 were 1.3*103,
39, 2.0*102, 0.13 and 1.3*103  pmol/l, respectively, and
these in the synovial fluid were 1.5*102, 18, 34, 0.30 and
2.3*102 pmol/l, respectively. The concentrations of miR-
16, miR-132, miR-146a, and miR-223 in synovial fluid
were significantly lower than those in plasma (P < 0.01, P
< 0.05, P < 0.01 and P < 0.05, respectively) (Figure 2A).
In OA, the average plasma concentrations of these
miRNAs were 1.1*103, 41, 2.1*102, 0.16 and 1.1*103 pmol/
l, respectively, and these in synovial fluid were 24, 13, 9.3,
7.8*10-2 and 4.6 pmol/l, respectively. The concentrations
of miR-16, miR-132, miR-146a and miR-223 in synovial
fluid were also significantly lower than those in plasma (P
< 0.01, P < 0.01, P < 0.01 and P < 0.01, respectively) (Fig-
ure 2B).
There were no correlations between plasma miRNA
concentrations and synovial fluid miRNA concentrations
(Figure S1 in Additional file 1), except miR-223 from OA
patients (r = 0.50, P = 0.01, n = 22). These findings imply
that synovial fluid and plasma miRNAs are distinctly gen-
erated.
Synovial tissues released miRNAs similar to synovial fluid 
miRNAs
To estimate the origin of plasma or synovial fluid miR-
NAs, FLSs, synovial tissues, PB MNCs, and synovial fluid
MNCs were cultured with serum-free medium for 48 h,
and miRNAs in the resultant conditioned medium were
measured (Figure 3A, B, C). There were no statistically
significant differences in analyzed miRNAs between RA
and OA. However, radar charts of the mean concentra-
tion of each miRNA showed the difference in secretion
patterns of miRNAs between tissues (Figure 3D). FLSs
and synovial tissues secreted miR-132 with relatively high
concentration, but rarely miR-223, while MNCs secreted
miR-223 and miR-155 moderately, but miR-16, miR-132
Figure 1 The presence of miRNAs in plasma and synovial fluid and their stability for storage. (Upper) Plasma and synovial fluid of RA were stored 
in --20°C until indicated days, thawed and analyzed for the concentrations of the indicated miRNAs. (Lower) The concentrations of indicated miRNAs 
in plasma and synovial fluid of RA after indicated freeze-thaw cycles from --20°C to 4°C. Significant differences compared to the concentration after 
the first freeze-thaw are indicated by * = P < 0.05, ** = P < 0.01. Results represent three independent experiments.Murata et al. Arthritis Research & Therapy 2010, 12:R86
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Figure 2 Comparisons between miRNA concentrations in plasma and those in synovial fluid. A and B, Plasma and synovial fluid concentrations 
of miR-16, miR-132, miR-146a, miR-155 and miR-223 in RA (A) and OA (B). The average concentrations of these miRNAs were quite different. Significant 
differences between plasma and synovial fluid are indicated by * = P < 0.05, ** = P < 0.01.Murata et al. Arthritis Research & Therapy 2010, 12:R86
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Figure 3 The concentrations of miRNAs in the condition medium of each cell or tissue of RA and OA. A, FLSs of RA (n = 4) and OA (n = 5) were 
cultured in serum-free medium for 48 h. Concentrations of miRNAs in each conditioned medium are shown. B, Synovial tissues of RA (n = 3) and OA 
(n = 3) were cultured in serum-free medium for 48 h. Concentrations of miRNAs in conditioned medium are shown. There were no statistically signif-
icant differences between RA and OA in A and B. C, PB MNCs of RA (n = 3), OA (n = 3) and HC (n = 3) were cultured in serum-free medium for 48 h. 
Concentrations of each miRNA in conditioned medium are shown. There were no statistically significant differences among RA, OA and HC. D, Radar 
charts show the average concentrations of each miRNA of each sample. Expression patterns of plasma miRNA of RA and OA were similar. Synovial 
fluid miRNAs were similar to the miRNAs secreted by synovial tissues.Murata et al. Arthritis Research & Therapy 2010, 12:R86
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and miR-146a at relatively low level. Plasma miRNAs
seemed to originate not limited just MNCs because miR-
146a in plasma was relatively higher than that secreted by
MNCs. Rader charts also indicated that synovial fluid
miRNAs and plasma miRNAs have different origins
because of the different patterns in miR-132 and miR-155
(Figure 3D). Interestingly, synovial fluid miRNAs of OA
were most similar to miRNAs secreted by synovial tis-
sues. In RA, the expression pattern of miR-16, miR-132,
miR-146a, and miR-155 of synovial fluid was similar to
that secreted by synovial tissues, while synovial fluid
miR-223 was relatively high compared to miR-223
secreted by synovial tissues. Synovial tissues appear a
main source of synovial fluid miRNAs, but synovial fluid
miR-223 reflects the influence of cells including MNCs
infiltrating into synovial fluid. These results indicate that
synovial fluid miRNAs reflect the condition of joint
space.
Plasma miRNAs differentiated RA and OA from HC
P l a s m a  m i R N A s  h a v e  b e e n  e x p e c t e d  a s  b i o m a r k e r s  o f
malignant tumors [14,17]. To determine whether plasma
miRNAs can be clinical markers for RA or OA, plasma
samples from RA, OA patients and HC were analyzed
(Figure 4A). As suggested in radar charts (Figure 3D),
plasma miR-132 of patients with RA or OA was lower
than that of HC with statistical significances (P < 0.01 or
P < 0.01). Plasma miR-16 of patients with OA was lower
than that of HCs with statistical significance (P < 0.05).
Thus, investigated plasma miRNAs of RA and those of
OA were somehow similar, but significantly different
from those of HC.
Plasma miR-132 can be a potential diagnostic marker for 
patients with RA and OA
To determine the diagnosability of plasma miR-132 for
patients with RA or OA, we conducted a ROC analysis of
miR-132 (Figure 5A, B). Plasma miR-132 test at a cutoff
value of 67.8 pmol/l could detect individuals with RA at
83.8% of sensitivity and 80.7% of specificity, and plasma
miR-132 test at a cutoff value of 67.1 pmol/l could also
detect individuals with OA at 84.0% of sensitivity and
81.2% of specificity. Area under the ROC curve (AUC) of
each plot was not lower than 0.90, indicating high diag-
nosability of each test.
Synovial fluid miRNAs differentiated RA and OA
While analyzed plasma miRNAs failed to differentiate RA
and OA, synovial fluid miRNAs had a possibly to differ-
entiate them because synovial fluid miRNAs reflected the
condition of joint space more than plasma miRNAs (Fig-
ure 3D). Synovial fluid miR-16, miR-146a miR-155 and
miR-223 of patients with RA were higher than those of
patients with OA with statistical significances (P < 0.01, P
< 0.05, P < 0.05 and P < 0.05, respectively) (Figure 4B).
Additionally we compared ratio of concentration of each
synovial fluid miRNA to plasma miRNA (SF/PB ratio)
between RA and OA (Figure S2 in Additional file 2). Sim-
ilar to the result of synovial fluid miRNAs, SF/PB ratios of
miR-16, miR-146a miR-155 and miR-223 were signifi-
cantly higher in RA than those in OA (P < 0.05, P < 0.05, P
< 0.01, P < 0.01, respectively). These results indicate that
synovial fluid miRNAs can be a useful tool for diagnosis
of RA and OA, and for the analysis of their pathogenesis.
Plasma miRNAs and synovial fluid miRNAs correlate with 
clinical variables
To assess the possibility of plasma and synovial fluid miR-
NAs as biomarkers of RA, we investigated the correlation
of miRNAs with clinical variables including serum matrix
metalloproteinase-3 (MMP-3), C-reactive protein (CRP),
Erythrocyte Sedimentation Rate (ESR), 28-joint Disease
Activity Score (DAS28), swollen joint count (SJC) and
tender joint count (TJC). Although plasma miRNAs did
not significantly correlate with MMP-3, CRP, or ESR,
plasma miR-16, miR-146a, miR-155, and miR-223
inversely correlated with TJC (r = - 0.55, P < 0.01, n = 30;
r = - 0.54, P < 0.01 n = 30; r = - 0.45, P = 0.03, n = 30; r = -
0.49,  P  = 0.02, n = 30; respectively) (Figure. 6A), and
plasma miR-16 also inversely correlated with DAS28 (r =
- 0.45, P = 0.03, n = 30) (Figure 6C). Unexpectedly, syn-
ovial fluid miRNAs had no correlations with clinical vari-
ables of RA including DAS28 (Figure 6D). Then, we
hypothesized the relative expression of synovial fluid
miRNAs compared to plasma miRNAs would more
reflect the condition of joint of RA than absolute concen-
tration of synovial fluid miRNAs. Dot plots of TJC and
SF/PB ratio are shown in Figure 6B. Although SF/PB ratio
of each miRNA failed to correlate with DAS28 (data not
shown), SF/PB ratio of miR-16, miR-132 and miR-146a
correlated with TJC (r = 0.71, P < 0.01, n = 20; r = 0.67, P
< 0.01, n = 20; and r = 0.80, P < 0.01, n = 20) at higher R2
values than plasma miRNAs.
Discussion
Tissue miRNAs have been noted not only as key mole-
cules in intracellular regulatory networks for gene expres-
sion, but also as biomarkers for various pathological
conditions [26]. Recent studies suggest that miRNAs in
plasma can be biomarkers for the diagnosis of lung, col-
orectal and prostate cancer [14,27]. Plasma miRNAs are
also suggested to be potential biomarkers for drug-
induced liver injury, and myocardial injury [28,29]. In this
report, we showed the presence and the stability of miR-
NAs in synovial fluid and plasma. We also found that the
expression of miRNAs in synovial fluid was distinct from
that in plasma and may reflect the condition of joint
space. Consistently, synovial fluid concentrations of miR-
16, miR-146a, miR-155 and miR-223 were significantlyMurata et al. Arthritis Research & Therapy 2010, 12:R86
http://arthritis-research.com/content/12/3/R86
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Figure 4 The concentrations of plasma and synovial fluid miRNAs in RA and OA. A. Plasma concentrations of miR-16, miR-132, miR-146a, miR-
155 and miR-223 in RA, OA and HC. The plasma concentration of miR-16 in OA was significantly lower than HC. The plasma concentrations of miR-132 
in RA and OA were significantly lower than HC. B. Synovial fluid concentrations of indicated miRNAs in RA and OA. The concentrations of miR-16, miR-
146a miR-155, miR-223 in RA were significantly higher than those in OA. Significant differences are indicated by * = P < 0.05, ** = P < 0.01.Murata et al. Arthritis Research & Therapy 2010, 12:R86
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higher in RA than those in OA. Finally we referred the
possibility of plasma and synovial fluid miRNAs as poten-
tial biomarkers of RA.
We quantified miRNAs by real-time PCR after using
NCode VILO miRNA cDNA Synthesis Kit. This kit poly-
adenylates miRNAs and reverse-transcribes with a
poly(T) adapter as reverse primer. Because the specificity
of this procedure depends on the annealing of the for-
ward primer to the sequence of mature miRNA in the
amplicon during amplification, there is a low possibility
that pre-miRNAs are also amplified [30]. To exclude the
contamination of pre-miRNAs and nonspecific amplifi-
cation, we performed TA cloning of PCR products. We
verified that all the inserted size was approximately 60
nucleotides by electrophoresis, and that sequences were
correct. These results were probably attributed to low
abundance of pre-miRNAs and difficulties in polyadeny-
lation of pre-miRNA due to the presence of the stem loop
structure [31]. Even if there remains little possibility to
amplify pre-miRNA, we think that procedures used in
this study are useful for diagnosis and determination of
activities.
Plasma miRNAs have been shown to be remarkably sta-
ble in plasma and protected from endogenous RNase
activity [14]. In previous reports, plasma miRNAs are sta-
ble at room temperature for up to 24 h and resistant for
freeze-thawing from -80°C to room temperature up to
eight times. We additionally demonstrated that miRNAs
in synovial fluid were as stable as miRNAs in plasma and
that both of these miRNAs were also stable at -20°C for
up to seven days. These stabilities contribute to the hand-
iness of plasma and synovial fluid miRNAs as biomarkers.
Although we showed that synovial tissue is a main
source of synovial fluid miRNA, the mechanism for sta-
bility of synovial fluid miRNA remains to be determined.
In plasma, some miRNAs are thought to be secreted in a
form of exosomes, which are 50- to 90-nm membrane
vesicles abundant in plasma containing mRNAs and miR-
Figure 5 ROC curve analysis of plasma miR-132 to differentiate patients with RA or OA from HCs. A. ROC plot of plasma miR-132 for the diag-
nosis of RA. AUC was 0.90. A cutoff value of 67.8 pmol/l diagnosed RA at the sensitivity of 83.8% and the specificity of 80.7%. B. ROC plot of plasma 
miR-132 for the diagnosis of OA. AUC was 0.91. A cutoff value of 67.1 pmol/l diagnosed OA at the sensitivity of 84.0% and the specificity of 81.2%.Murata et al. Arthritis Research & Therapy 2010, 12:R86
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Figure 6 Correlation between disease activities of RA and miRNAs in plasma or synovial fluid. TJC correlated with plasma miRNAs (A) or SF/PB 
ratio of miRNA (B). DAS28 correlated with plasma miRNAs (C), but not with synovial fluid miRNAs (D). r values of Pearson's product-moment correla-
tion and P-values of their null hypothesis are shown. Regression lines are shown when P values are less than 0.1.Murata et al. Arthritis Research & Therapy 2010, 12:R86
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NAs [32-34]. Exosomes released from various cells can
transfer proteins and RNA between cells, facilitating pro-
cesses such as antigen presentation and in trans signaling
to neighboring cells [34-37]. However, other mechanisms
for stabilization may exist (for example, in a RNA-
induced silencing complex (RISC)), because some miR-
NAs were reported to be biomarkers of tissue injury (for
example, liver, heart, kidney, et al.). Exosomes were
shown to exist in synovial fluid [38], but there have been
no report about the existence of miRNA in synovial fluid
or its exosomes.
Investigated miRNAs in this study have already been
shown to associate with RA or OA. miR-16 and miR-132
were shown to be upregulated in PB MNCs of RA
patients [21]. Although the function of miR-16 and miR-
132 in RA has not been determined yet, miR-16 is present
in high levels in most of cells and thought to be poten-
tially a master miRNA involved in determining mRNA
stability via AU-rich element sites [39]. miR-146a is
upregulated in PB MNCs, FLS and synovial tissue of RA
[19-21] and expressed in cartilage of low-grade OA [40].
The targets of miR-146a/b are IL-1β and TRAF6, which is
a key molecule in the down stream of TNFα and IL-1β
signaling [41]. The expression of miR-155 is upregulated
in RA FLS and has repressive effect to MMP-3 and 1 [18].
The expression of miR-223 is down regulated in RA FLS
[19].
Our hypothesis was that in RA patients, miR-16, miR-
132, miR-146 and miR-155 were upregulated in plasma
and synovial fluid, but miR-223 down regulated. How-
ever, there were no statistically significant differences
between plasma miRNAs of RA and those of OA. These
results are not inconsistent with the previous report:
Expression patterns of exosomal miRNAs were shown to
be different from those of intracellular miRNAs [34],
though we could not directly show that the synovial fluid
miRNA exist in the form of exosome. W e showed syn-
ovial fluid miRNAs were similar to miRNAs secreted by
synovial tissues, while plasma miRNAs were different
from miRNAs secreted by MNCs. These facts suggest
that synovial tissues and infiltrating cells are a main
source of synovial fluid miRNAs, while plasma miRNAs
are generated by various tissues.
In this study, all healthy controls were younger than 66
years old according to the request of our ethical commit-
tee, while patients with OA were older than 64 years old.
When the age of patients and healthy controls was lim-
ited from 40 to 60 years to match the age background of
groups, plasma miR-132 of HC (n = 9) was still signifi-
cantly higher than that of RA (n = 16) (P < 0.01). This
result suggests that the difference in age between groups
has little effect on our analyses.
Plasma concentration of miR-132 differentiated
patients with RA or OA from HC, though plasma and
synovial fluid miR-132 failed to differentiate RA from
OA. Furthermore, plasma miR-132 or its SF/PB ratio cor-
related with TJC. These results indicate that miR-132
might be involved in the systematic condition of patients
with joint inflammation.
On the other hand, miR-16, miR-146a, miR-155 and
miR-223 were higher in RA synovial fluids than in OA
synovial fluids. Although these miRNAs of plasma had no
differences between RA and OA, they significantly corre-
lated with TJC, and plasma miR-16 also correlated with
DAS28. Moreover, SF/PB ratio of miR-16 and miR-146a
also correlated with TJC with moderate R2 values. These
collectively imply that miR-16, miR-146a miR-155 and
miR-223 are involved in the pathogenesis specific for RA.
As reported in the field of malignant tumors [14,16,17],
disease specific plasma miRNAs for RA or OA are
expected. Although investigated plasma miRNAs failed
to differentiate RA and OA, disease specific miRNAs that
are not investigated in this study may exist. In our prelim-
inary study, miR-124a, miR-142-3p, miR-142-5p, and
miR-133a were also detectable. Further analysis for com-
prehensive plasma and synovial fluid miRNAs using
larger number of samples including age-matched RA and
OA patients with various severity and healthy controls
are expected.
Conclusions
In this study, we have firstly shown that miRNAs are pres-
ent and stable in synovial fluid. Synovial fluid miRNAs
showed distinct profiles from plasma miRNAs, implying
generated chiefly from synovial tissues, and clearly differ-
entiated RA and OA. Synovial fluid and plasma miRNAs
can be promising diagnostic biomarkers and potential
sources for analyzing roles of miRNAs in RA and OA.
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